Study unravels the hidden genomic complexity of the giant mimivirus

A study published online today in the journal Genome Research offers surprising new clues into the genomic complexity of the giant Mimivirus, the largest known virus in the world. Previous studies have shown that unlike most viruses, the Mimivirus has more genes than many bacteria and performs functions that normally occur only in cellular organisms. The results of the most recent study, led by a team from the Structural and Genomic Information Laboratory at the Mediterranean Institute of Microbiology in Marseille, France, suggest that the Mimivirus is even more complex than previously thought.

Using the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company, the researchers performed the first ever viral transcriptome analysis by deep sequencing RNAs expressed by infected amoebas throughout the Mimivirus replication cycle (1). Unexpectedly, the analysis revealed 75 new genes, including 26 producing non-coding RNAs. The existence, and so far unknown function, of these additional genes in the already plethoric Mimivirus genome could radically change the current understanding of the way large viruses operate.

Since the discovery and deciphering of its genome in 2004, the giant Mimivirus has blurred the traditional boundaries between viruses and cellular organisms, spurring debate between virologists and evolutionary biologists. In a quest to fully characterize the Mimivirus transcriptome and obtain new insights into its gene and protein functions, the researchers turned to the Genome Sequencer FLX System. “Not only were we able to confirm the 910 previously predicted protein-coding genes, but we also identified 75 novel genes in the Mimivirus,” explained Jean-Michele Claverie and Chantal Abergel, senior authors of the study. “The long reads generated by the GS FLX System were critical for the assembly of full length transcripts, identification of polycistronic mRNA and for the discovery of short transcripts, since the 5’ and 3’ tags were contained within a single read.”

Sequence mapping also allowed the precise delineation of most promoter regions and the identification of the sequence motif governing the early versus late expression of Mimivirus genes. Excitingly, the study revealed a new promoter element correlating with late gene expression that is also prominent in Sputnik, the recently described Mimivirus “virophage”.

Moving forward, the researchers plan to perform similar viral transcriptome analysis in the presence and absence of various inhibitors, and with other amoeba strains that have different sensitivity to the Mimivirus. Since recent metagenomics studies suggest that Mimivirus could be the prototype of numerous marine viruses infecting a variety of planktonic micro-organisms, a specific program is devoted search for the Mimivirus’ marine relatives in the ongoing international TARA-Oceans expedition.

“We are pleased to see continued widespread adoption of 454 Sequencing systems in virology research,” said Ulrich Schwoerer, Head of Global Marketing at 454 Life Sciences. “This particular study demonstrates, for the first time, the unique capabilities of the technology for comprehensive transcriptome analysis of viral genomes. We are excited to follow the team’s continued work in this field.”
 

06.04.2010

More on the subject:
Read all latest stories

Related articles

Photo

microRNAs hint at cognitive decline

Researchers find warning signs for dementia in the blood

esearchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the blood that can indicate impending dementia. Their findings, which are presented in the…

Photo

Bioengineering

Lab-grown muscle offers insights for neuromuscular diseases

In the fight against diseases like amyotrophic lateral sclerosis (ALS), biomedical engineering researchers at the University of Southern California have created a powerful lab model to better see how…

Photo

Patient response testing

New method predicts which cancer therapies work (and which don't)

A new technology that can study which therapies will work on patients with solid cancerous tumours has been developed by scientists at University College London (UCL). Researchers say the tool, which…

Related products

Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
ASP Lab Automation – Tube Sorter SortPro

Sample Processing

ASP Lab Automation – Tube Sorter SortPro

ASP Lab Automation AG
Beckman Coulter – Access Interleukin-6 (IL-6)

Immunoassays

Beckman Coulter – Access Interleukin-6 (IL-6)

Beckman Coulter, Inc.
Beckman Coulter – DxA 5000

Sample Processing

Beckman Coulter – DxA 5000

Beckman Coulter, Inc.
Beckman Coulter – DxH 500 Family

Blood Cell Counter

Beckman Coulter – DxH 500 Family

Beckman Coulter, Inc.
Subscribe to Newsletter